ABSTRACT
Objectives Immunocompromised patients are at risk of severe coronavirus disease 2019 and are considered a high priority for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Humoral vaccination response is impaired in these patients when circulating B cells are lacking. We aimed to analyze B-cell subsets at the time of vaccination to identify potential predictors of humoral vaccination response.
Methods Patients (n=120) receiving B-cell-depleting therapy (n=41), those suffering from inborn errors of immunity (n=25) and hematologic malignancies (n=56), and healthy controls (n=79) were vaccinated twice with BNT162b2 or mRNA-1273. B-cell subsets were analyzed prior to vaccination. Two independent anti-SARS-CoV-2 S immunoassays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed three to four weeks after the second vaccination.
Results Seroconversion occurred in 100% of the healthy controls, in contrast to 67% (RBD) and 82% (TSP) of the patients, while only 32% (RBD) and 22% (TSP) achieved antibody levels comparable to those of healthy controls. The number of circulating naïve B cell was strongly associated with antibody levels (r=0.761, P<0.001) across all immunosuppressive treatments or conditions. In multivariable analysis, the number of naïve B cells was an independent predictor for achieving antibody levels comparable to healthy controls, and receiver operating characteristic analysis predicted that at least six naïve B cells per µL were required.
Conclusions Assessing the abundance of naïve B cells in immunocompromised patients could be useful in predicting the optimal vaccination response.
What is already known about this subject?
▸ Humoral vaccination response is impaired in patients with immunodeficiency or B-cell-depleting therapies, such as anti-CD20 antibody therapy or hematopoietic stem cell transplantation.
▸ Current recommendations advise an interval of six months between the most recent anti-CD20 antibody administration and vaccination.
What does this study add?
▸ Immunocompromised patients can achieve anti-spike protein antibody levels similar to those in healthy subjects after vaccination.
▸ Independent of concurrent immunosuppressive treatment or condition, the number of naïve B cells, but not the total number of B cells, is strongly associated with anti-spike protein antibody levels, similar to that in healthy subjects.
How might this impact on clinical practice or future developments?
▸ Assessment of the abundance of naïve B cells in immunocompromised patients could be used to schedule vaccinations for optimal antibody responses.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04858607
Funding Statement
no external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethikkomission der Medizinischen Universitaet Graz
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data will be shared upon request.
